Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;16(6):13-20.
doi: 10.3747/co.v16i6.426.

Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer

V C Tam  1 , S Rask, T Koru-Sengul, S Dhesy-Thind
Affiliations

Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer

V C Tam et al. Curr Oncol. 2009 Dec.

Abstract

Background: The relevance of oncology trial results to clinical practice depends on whether the trial participants are similar to the actual population of patients receiving treatment for the malignancy and whether the patients are treated similarly in both circumstances. Chemotherapy treatments may be more toxic in patients of advanced age and poor performance status-patients typically excluded from clinical trials.

Methods: In a retrospective chart review that included all non-trial patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy from January 2004 to September 2006 at our institution, we quantified and subsequently compared the toxicity rates of the irinotecan regimens in clinical practice with published toxicity rates from corresponding phase iii clinical trials. The primary endpoint was the incidence of grades 3 and 4 diarrhea.

Results: The study included 203 patients, and the irinotecan regimens considered included FOLFIRI [irinotecan, leucovorin, 5-fluorouracil (5fu)],IFL (bevacizumab, irinotecan, 5FU, leucovorin),XELIRI (capecitabine, 3-weekly irinotecan), andirinotecan monotherapy. The rates of grades 3 and 4 diarrhea for FOLFIRI, IFL, XELIRI, and irinotecan monotherapy in clinical practice were 10%, 15%, 17%, and 21% as compared with 10%, 23%, 20%, and 31% respectively in clinical trials. When only patients meeting trial performance status and age criteria were analyzed, the rates of grades 3 and 4 diarrhea by regimen were 11%, 20%, 19%, and 26% respectively.

Conclusions: Overall, the toxicity rates for FOLFIRI and irinotecan monotherapy in non-trial patients were not statistically different from the rates quoted in published clinical trials.

Keywords: Colorectal neoplasms; clinical trials; drug therapy; drug toxicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Method of patient selection. jcc = Juravinski Cancer Centre; capiri = capecitabine–irinotecan.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants, and nonparticipants. Cancer. 2006;106:2452–8. - PubMed
    1. Hori A, Shibata T, Kami M, et al. Age disparity between a cancer population and participants in clinical trials submitted as a new drug application of anticancer drugs in Japan. Cancer. 2007;109:2541–6. - PubMed
    1. Mayers C, Panzarella T, Tannock IF. Analysis of prognostic effects of inclusion in clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 2001;91:2246–57. - PubMed
    1. Cottin V, Arpin D, Lasset C, et al. Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol. 1999;10:809–15. - PubMed
    1. Fossa SD, Skovlund E. Selection of patients may limit generalizability of results from cancer clinical trials. Acta Oncol. 2002;41:131–7. - PubMed

LinkOut - more resources